Veloci

Veloci is a clinical-stage biotechnology company focused on developing next-generation T-cell receptor (TCR) therapies for the treatment of solid tumors. The company's proprietary Veloci platform integrates high-throughput TCR discovery with advanced engineering to create TCR-T cell therapies with optimized affinity and specificity. Its lead program, V-101, is an autologous TCR-T therapy targeting the MAGE-A4 antigen, currently in Phase 1 clinical development for patients with various advanced solid tumors. Headquartered in South San Francisco, Veloci is supported by a syndicate of premier life science investors, including GV, ARCH Venture Partners, and F-Prime Capital. The company aims to overcome the limitations of current cell therapies in the solid tumor microenvironment through its innovative approach to TCR design and T-cell fitness. Veloci was formerly known as Veloci-T before rebranding in 2023 to reflect its expanding capabilities in precision immunotherapy.